Inhibition of microRNA-34a mediates protection of thymosin beta 4 in endothelial progenitor cells against advanced glycation endproducts by targeting B-cell lymphoma 2.

In conclusion, inhibition of microRNA-34a mediated protection of thymosin beta 4 in endothelial progenitor cells against advanced glycation endproducts by targeting B-cell lymphoma 2, which was helpful for understanding the therapeutic potential of thymosin beta 4 for diabetic patients. PMID: 31397599 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31397599?dopt=Abstract

Source: Canadian Journal of Physiology and Pharmacology - August 8, 2019 Category: Drugs & Pharmacology Authors: Chen Q, Shen Z, Mao Y, Li Q, Liu Y, Mei M, Qiu F, Wang M Tags: Can J Physiol Pharmacol Source Type: research